Drug-resistant Trials

Trials for Gleevec, Sutent, Stivarga resistant GIST

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Phase I trials are included in this listing. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov. The drug name listed will be the most advanced available; i.e., brand name first or generic name and if neither of those are available, IND.

18 trials found
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase:  3
Category:   KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Mid Florida Hematology and Oncology Center Orange City FL USA
University of Toledo Medical Center Toledo OH USA
City of Hope Duarte CA USA
Medstar Hospital Washington Washington DC USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Orlando Health UF Health Cancer Center Orlando FL USA
University of Michigan Ann Arbor MI USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Fox Chase Cancer Center Philadelphia PA USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
UAB Comprehensive Cancer Center Birmingham AL USA
Mayo Clinic in Arizona Scottsdale AZ USA
UCLA Hematology/Oncology Santa Monica CA USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
Mayo Clinic, Jacksonville Jacksonville FL USA
H. Lee Moffit Cancer Center Tampa FL USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Mayo Clinic, Rochester Rochester MN USA
Roswell Park Cancer Institute Buffalo NY USA
Memorial Sloan Kettering New York NY USA
Duke University Durham NC USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
University of Washington - Seattle Cancer Care Alliance Seattle WA USA
Carbone Cancer Center, University of Wisconsin Madison WI USA
Sir Charles Gairdner Hospital Nedlands Western Australia Australia
Princess Margaret Hospital Toronto ON Canada
Arhus University Hospital Arhus Denmark
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Hopital Edouard Herriot Lyon France
Hospital de La Timone Marseille France
Centre Eugene Marquis Rennes Isle-et-Vilane France
St. Herblain Saint-Herblain Loire Atlantique France
Centre Hospitalier Universitaire Toulouse Purpan Toulouse Haut-Garonne France
Institut Gustave Roussy Villejuif Val de Narne France
Helios Klinikum Bad Saarow Bad Saarow Germany
Helios Klinikum Berlin-Buch Berlin Germany
Medizinische Hochshule Hannover Hannover Germany
Medical Oncology University Debrecen Debrecen Hungary
National Cancer Centre Goyang Republic of Korea
Seoul National University Hospital Seoul Republic of Korea
Asan Medical center Seoul Songpa-gu Republic of Korea
Samsung Medical Center Seoul Republic of Korea
University Medical Center Groningen Groningen Netherlands
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands
Dept of Oncology, Haukeland University Hospital Bergen Norway
Oslo University Hospital Oslo Norway
Hospital Universitari Vall d'Hebrón Barcelona Spain
Hospital Universitario Clínico San Carlos Madrid Spain
Fundacion Jimenez Diaz Madrid Spain
Dept. of Oncology, Skane University Lund Sweden
Karolinska University Hospital Solna Sweden
Taipei Veterans General Hospital Taipei Taiwan
China Medical University Hospital Taichung Taiwan
University of Colorado Aurora CO USA
University of Arizona Cancer Center Tucson AZ USA
Ubiversity of California San Francisco San Francisco CA USA
University ofKansas Cancer Center Kansas City KS USA
University of Tennessee Knoxville TN USA
Bankstown-Lidcombe Hospital Bankstown Australia
CEPHO-Centro de Estudos e Pesquisas de Hematologia e Oncologia Sao Paulo Sao Paulo Brazil
Centro de Oncologia de Precision, Iniversidad Mayor Santiago Chile
Humanity & Health Clinical Trial Centre Central Hong Kong China
Hong Kong United Oncology Centre Jordan Hong Kong China
Prince of Wales Hospital Sha Tin Hong Kong China
Korea University Guro Hospital Seoul Republic of Korea
Hospital Clinico de Santiago de Compostela Santiago de Compostela Spain
National Taiwan University Hospital New Taipei City Taiwan
Azienda Ospedaliera Universitaria Careggi Rozzano Italy
Ohio State University Comprehensive Cancer Center Columbus OH USA
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo Italy
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
Hospital 12 octobre Madrid Spain
Instituto Alaxender Fleming Buenos Aires Argentina
Azianda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento Verona Italy
Centrum Onkologii im. Prof. Franciszka Lukaszczyka Bydgoszcz Poland
Tom Baker Cancer Center Calgary AB Canada
Azienda Ospedaliera Spedali Civili di Brescia-Oncology Brescia Italy
AOUC Azienda Ospedaliero - Universitaria Careggi Firenze Italy
Istituto Romagnolo per lo Studio dei Tumors "Dino Amadori" Medola Italy
Erasmus Medical center Rotterdam Netherlands
Hospital Virgen del Rocio Sevilla Spain
University College Hospital London UK
Royal Marsden Hospital - Chelsea London UK
lnstituto Nacional de Cancer - INCA Rio De Janeiro Brazil
Centro de Oncologia de Precision, Universidad Mayor Instituto Oncologico FALP Santiago Chile
Masarykuv onkologicky ustav Brno Czechia
Policlinico Universitario Campus Bio-Medico Roma Italy
I Can Oncology Center SA De CV Monterrey Mexico
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej Gliwice Poland
Nebraska Methodist Hospital Omaha NB USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
UNICAMP - Hospital das Clinicas Campinas Brazil
Cross Cancer Institute Edmonton AB Canada
Maisonneuve-Rosemont Hospital Montreal QC Canada
Institut Bergonie Bordeaux Gironde France
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Universistatsklinikum Mannheim Mannheim Germany
Istituto Nazionale Dei Tumori Milan Italy
Instituto Europeo di Oncologia Milano Italy
Marie Sklodowska-Curie Memorial Cancer Center Warsaw Poland
Hospital San Pau Barcelona Spain
Hospital Universitairio Virgen de la Arrixaca Murcia Spain
Hospital Universitario Gregorio Maranon Madrid Spain
hospital Universitario Miguel Servet Zaragosa Spain
Chang Gung Memorial Hospital Linkou Taoyuan County Taiwan
The Beatson Institute Glasgow UK
Guy's Hospital London UK
Christie Hospital NHS Trust Manchester Lancashire UK
Instituto Oncologico de Cordoba (IONC) Cordoba Argentina
Fakultni nemocnice Hradec Kralove Hradec Kralove Czechia
Fakultni nemocnice Olomouc - Oncology clinic Olomouc Czechia
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola Bologna Italy
IRCCS La Fondazione e l'Istituto di Candiolo Candiolo Italy
Centro de Investigacion Medica Aquascalientes (CIMA) Aguascalientes Mexico
Oaxaca Site Management Organization S.C. Oaxaca Mexico
Szpital Specjalistyczny w Brzozowie Brzozow Poland
Institut Catala d'Oncologia - L'Hospitalet Barcelona Spain
Chang Gung Memorial Hospital - Kaohsiung Branch Kaohsiung Taiwan
 


Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Phase:  3
Category:   KIT/PDGFRA inhibitor + VEGF inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
PLA General Hospital Beijing China
 


A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)
Phase:  3
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Oregon Health & Science University Portland OR USA
Princess Margaret Hospital Toronto ON Canada
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Dana Farber Cancer Institute Boston MA USA
Memorial Sloan Kettering New York NY USA
 


A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)
Phase:  2
Category:   PD-L1 + KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Marie Sklodowska-Curie Memorial Cancer Center Warsaw Poland
 


ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
Phase:  2
Category:   KIT/PDGFRA/VEGF inhibitors
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
 


A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)
Phase:  2
Category:   KIT/PDGFRA inhibitor + PD-L1 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Centre Léon Bérard Lyon Rhone France
La Timone University Hospital, Medical Oncology Unit Marseille Bouches du Rhone France
Hopital Robert Debre Reims Marne France
Institut Gustave Roussy Villejuif Val de Narne France
ICANS Institut de Cancérologie Strasbourg Strasbourg France
 


Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)
Phase:  2
Category:   KIT/PDGFra/RET/FGFR/VEGFR inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Institut Paoli Calmette Marseilles Bouches-du-Rhône France
Centre Léon Bérard Lyon Rhone France
La Timone University Hospital, Medical Oncology Unit Marseille Bouches du Rhone France
Centre George Francois Leclerc Dijon Bourgogne-Franche-Comté France
Institut Bergonie Bordeaux Gironde France
Centre Hospitalier Universitaire Toulouse Purpan Toulouse Haut-Garonne France
Centre Oscar Lambret - Lille Lille Nord France
Centre Eugene Marquis Rennes Isle-et-Vilane France
St. Herblain Saint-Herblain Loire Atlantique France
CHU de Reimes - Hôpital Pontchaillou Reims Marne France
Institut de Cancérologie de Lorraine Vandoeuvre-les-Nancy Meurthe et Moselle France
Institut Gustave Roussy Villejuif Val de Narne France
CHU Poitiers - Hospital la Miletrie Poitiers Vienne France
Centre Antoine LACASSAGNE Nice Alpes-Martines France
 


Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
Phase:  2
Category:   Tubulin inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Fox Chase Cancer Center Philadelphia PA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
MD Anderson Cancer Center Houston TX USA
 


A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Phase:  1
Category:   HSP90 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Site name unknown, Osaka Osaka Japan
Site name unknown, Tokyo Tokyo Japan
Site name unknown - Kaohsiung Kaohsiung County Taiwan
Site name unknown - Taipei Taipei Taiwan
Site name unknown - Adelaide - Taiho Adelaide Australia
Alfred Health (Medical Oncology) Melbourne Melbourne VIC Australia
Site name unknown - Chiba - Taiho Chiba Japan
Site name unknown - HoKkaido - Taiho Hokkaido Japan
Site name unknown - Linkou - Taiho Linkou Taiwan
Site name unknown - Singapore - Taiho Singapore Singapore
 


A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase:  1/2
Category:   ULK1/2 inhibitor + KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
START Midwest Michigan, PC Grand Rapids MI USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
New York University New York NY USA
Memorial Sloan Kettering New York NY USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Oregon Health & Science University Portland OR USA
 


A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
Phase:  1/2
Category:   Kit inhibitor + PD-L1 Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Régional de Lutte contre le Cancer de Montpellier Montpellier Herault France
Institut Claudius Regaud Toulouse France
 


Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Phase:  2
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
University of Iowa Hospitals and Clinics Iowa City IA USA
University of Michigan Ann Arbor MI USA
Washington University School of Medicine St. Louis MO USA
Mount Sinai School of Medicine New York NY USA
Abramson Cancer Center - University of Pennsylvania Philadelphia PA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Peking University First Hospital-Urology Beijing Beijing China
Prince of Wales Hospital Randwick New South Wales Australia
Royal Melbourne Hospital Parkville Victoria Australia
Tom Baker Cancer Center Calgary AB Canada
Princess Margaret Hospital Toronto ON Canada
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
CHRU Strasbourg - Hôpital Hautepierre Strasbourg France
Institut Paoli-Calmette Marseille Bouches du Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Hopital Edouard Herriot Lyon France
University of Freiburg - Tumor Biology Center Freiburg Germany
Charite Comprehensive Cancer Center (CCCC) Berlin Germany
Instituto Europeo di Oncologia Milano Italy
Hokkaido University Hospital Hokkaido Japan
Universitair Medisch Centrum Utrecht Netherlands
National Cancer Center Singapore Singapore
Hospital 12 octobre Madrid Spain
Hospital Vall d'Hebron Barcelona Spain
Dept. of Oncology, Skane University Lund Sweden
Dept. of Oncology, Academic Hospital Uppsala Sweden
Beatson West of Scotland Cancer Centre Glasgow UK
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Sheba Medical Center Rahat Israel
Azianda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento Verona Italy
National Cancer Center Hospital Chuo-ku Tokyo Japan
Karolinska University Hospital Solna Sweden
Dept. of Oncology, Sahlgrenska University Hospital Gothenburg Sweden
Cambridge University Hospitals Cambridge UK
Massachusetts General Hospital Boston MA USA
Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China
West China Hospital of Sichuan University Cheng Du Sichaun China
Rigshospitalet-Department of Endocrinology Copenhagen Hovedstaden Denmark
Odense Universitetshospital Odense Syddanmark Denmark
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre Paris France
Hopitaux Universitaires Paris Centre-Hopital Cochin Paris France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen Munchen Bayern Germany
Comprehensive Cancer Center Mainfranken Wurzburg Bayern Germany
Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály Budapest Hungary
University of Naples Federico II Naples Campania Italy
Ospedale San Raffaele-Oncologia Medica Milano Lombardia Italy
Azienda Ospedaliera Spedali Civili di Brescia-Oncology Brescia Italy
Yokohama City University Hospital Yokohama Kanagawa Japan
Kochi Medical School Hospital Nankoku Kochi Japan
Kyoto University Hospital Kyoto Japan
Tokyo Women's Medical University Adachi Medical Center Tokyo Japan
Hospital Universitario Central de Asturias-Medical Oncology Oviedo Asturias Spain
MD Anderson Cancer Center-Oncology Madrid Madrid Spain
Ege University Medicine of Faculty Bornova Izmir Turkey
Hacettepe Universitesi-oncology hospital Ankara Turkey
Ankara City Hospital Ankara Turkey
Istanbul Universitesi Cerrahpasa-Medical Oncology Istanbul Turkey
Royal Free Hospital London England UK
Hammersmith Hospital-Medical Oncology London UK
 


A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Phase:  1
Category:   KIT inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Guangdong General Hospital Guangzhou Guangdong China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Chinese PLA General Hospital Beijing China
Fudan University Shanghai Cancer Center Shanghai China
Henan cancer hospital Zhengzhou Henan China
 


Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase:  1
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
City of Hope Duarte CA USA
Sarcoma Oncology Center Santa Monica CA USA
University of Colorado Aurora CO USA
Emory Winship Cancer Institute Atlanta GA USA
University of Chicago Chicago IL USA
University of Michigan Ann Arbor MI USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Abramson Cancer Center - University of Pennsylvania Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Inova Health System Fairfax VA USA
Memorial Sloan Kettering New York NY USA
START Midwest Michigan, PC Grand Rapids MI USA
Virginia Cancer Specialists Fairfax VA USA
Valkyrie Clinical Trials INC Los Angeles CA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
 


A Study of NB003 in Patients With Advanced Malignancies
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Memorial Sloan Kettering New York NY USA
Peking University School of Oncology Beijing China
Fudan University Shanghai Cancer Center Shanghai China
Stanford University Palo Alto CA USA
Dana Farber Cancer Institute Boston MA USA
Oregon Health & Science University Portland OR USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
MD Anderson Cancer Center Houston TX USA
Beijing Cancer Hospital Beijing Beijing China
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Asan Medical center Seoul Songpa-gu Republic of Korea
Samsung Medical Center Seoul Republic of Korea
Hospital Vall d'Hebron Barcelona Spain
Fundacion Jimenez Diaz Madrid Spain
Royal Marsden Hospital - Chelsea London UK
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Xiangya Hospital Central South University Changsha Hunan China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China
West China Hospital of Sichuan University Cheng Du Sichaun China
The Second Hospital of Anhui Medical University Hefei Anhui China
Peking University People's Hospital Beijing Beijing China
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing China
Fujian Cancer Hospital Fuzhou Fujian China
Sun Yat-sen University Cancer Center Guangzhou Guandong China
The First Affiliated Hospital of Sun Yat-sen University Guangzhou Guandong China
Harbin Medical University Cancer Hospital Ha'erbin Heilongjiang China
The Affiliated Drum Tower Hospital of Nanjing University Nanjing Jiangsu China
Liaoning Cancer Hospital & Institute Shenyang Liaoning China
The Affiliated Hospital of Qingdao University Qingdao Shandong China
The 2nd Hospital of Xi'An Jiaotong University Xi'an Shanxi China
Tianjin Medical University Cancer Institute & Hospital Tianjin Tianjin China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou Zhejian China
The First Affiliated Hospital of Zhejiang University school of medicine Hangzhou Zhejiang China
 


[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)
Phase:  1
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
City of Hope Duarte CA USA
Stanford Cancer Center Palo Alto CA USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Oregon Health & Science University Portland OR USA
Medizinische Universitat Innsbruk - Universitatklinil fur Nuklearmedizin Innsbruck Austria
Erasmus Medical center Rotterdam Netherlands
Hospital Vall d'Hebron Barcelona Spain
Cambridge University Hospitals Cambridge UK
University of Pittsburgh Cancer Institute Pittsburgh PA USA
 


Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
Phase:  2
Category:   TRK Inhibitor
Conditions:  Sarcoma

Site
City
State
Country
Stanford University Medical Center Palo Alto CA USA
Memorial Sloan Kettering New York NY USA
Fox Chase Cancer Center Philadelphia PA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Samsung Medical Center Seoul Republic of Korea
Inova Health System Fairfax VA USA
Ronald Reagan UCLA Medical Center Los Angeles CA USA
Massachusetts General Hospital Boston MA USA
Dana Farber Cancer Institute Boston MA USA
Wake Forrest Winston-Salem NC USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
University of Washington - Seattle Cancer Care Alliance Seattle WA USA
National Cancer Center Singapore Singapore
Hospital Vall d'Hebron Barcelona Spain
Medstar Hospital Washington Washington DC USA
Memorial Hospital Pembroke Pines FL USA
Thomas Jefferson University Philadelphia PA USA
West Virginia University Morgantown WV USA
Copenhagen University Hospital Copenhagen Denmark
St Vincent's University Hospital Dublin Ireland
Severance Hospital, Yonsei University Health System Seoul Republic of Korea
John Theurer Cancer Center at Hackensack Hackensack NJ USA
Avera Cancer Institute Sioux Falls SD USA
Fundacion Jimenez Diaz Madrid Spain
Institut Bergonie Bordeaux Gironde France
Seoul National University Hospital Seoul Republic of Korea
University College Hospital London UK
Roswell Park Cancer Institute Buffalo NY USA
University of Chicago Chicago IL USA
Barts Health NHS Trust Royal London London UK
University Hospital Southampton Southampton UK
Centro Integral Oncologico Clara Campal Madrid Spain
Instituto Purtugues de Oncologia do Porto Francisco Gentil Porto Portugal
University of North Carolina (UNC) Chapel Hill NC USA
National Cancer Center Hospital East Chiba Japan
Charite Comprehensive Cancer Center (CCCC) Berlin Germany
 


18 trials found